Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy

Journal of Neuroimmunology

Volumn 174, Issue 1-2, 2006, Pages 74-81

  Velicu, Simona ^a   Han, Yu ^a   Ulasov, Ilya ^a   Brown, Ian E ^a   Andaloussi, Abdel El ^a   Gajewski, Thomas F ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Brain tumors; Cytokines; Gene therapy; T cells; Tumor immunity; Vaccination

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; RAG2 PROTEIN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER RESISTANCE; CELL BASED GENE THERAPY; CONTROLLED STUDY; CROSS PRESENTATION; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FATALITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INTRACRANIAL TUMOR; MALE; MELANOMA CELL; MICROENVIRONMENT; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR REJECTION;

ABDOMINAL NEOPLASMS; ANIMALS; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CROSS-PRIMING; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 33646118982     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.01.016     Document Type: Article

References (38)

1. Blank C., Brown I., Peterson A.C., Spiotto M., Iwai Y., Honjo T., and Gajewski T.F. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64 (2004) 1140-1145
2. Blank C., Gajewski T.F., and Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol. Immunother. 54 (2005) 307-314
3. Blank C., Brown I., Kacha A.K., Markiewicz M.A., and Gajewski T.F. ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo. J. Immunol. 174 (2005) 3416-3420
4. Bursch W., Grasl-Kraupp B., Wastl U., Hufnagl K., Chabicovsky M., Taper H., and Schulte-Hermann R. Role of apoptosis for mouse liver growth regulation and tumor promotion: comparative analysis of mice with high (C3H/He) and low (C57Bl/6J) cancer susceptibility. Toxicol. Lett. 149 (2004) 25-35
5. Cham C.M., Xu H., O'Keefe J.P., Rivas F.V., Zagouras P., and Gajewski T.F. Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation. J. Biol. Chem. 278 (2003) 17044-17052
6. Cserr H.F., Harling-Berg C.J., and Knopf P.M. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol. 2 (1992) 269-276
7. Da Cunha S., Ferreira E., Ramos I., Martins R., De Freitas L., Borges J.L., Corte-Real R., Mota A., Melico-Silvestre A., and Furtado A.L. Cerebral toxoplasmosis after renal transplantation. Case report and review. Acta Med. Port. 7 Suppl. 1 (1994) S61-S66
8. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., and Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 3539-3543
9. Fenstermaker R.A., and Ciesielski M.J. Immunotherapeutic strategies for malignant glioma. Cancer Control 11 (2004) 181-191
10. Fritz R.B., Wang X., and Zhao M.L. The fate of adoptively transferred quiescent encephalitogenic T cells in normal and antigen-tolerized mice. J. Neuroimmunol. 107 (2000) 66-72
11. Gajewski T.F. Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1. Curr. Opin. Invest. Drugs 5 (2004) 1279-1283
12. Gajewski T.F. Update on vaccines for solid tumors. Clin. Adv. Hematol. Oncol. 2 (2004) 158-159
13. Galdeano A., Boyano M.D., Smith-Zubiaga I., and Canavate M.L. B16F10 murine melanoma cells express interleukin-2 and a functional interleukin-2 receptor. Tumour Biol. 17 (1996) 155-167
14. Glick R.P., Lichtor T., Mogharbel A., Taylor C.A., and Cohen E.P. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 41 (1997) 898-906 (discussion 906-897)
15. Goldsworth T.L., and Fransson-Steen R. Quantitation of the cancer process in C57BL/6J, B6C3F1, and C3H/Hej mice. Toxicol. Pathol. 30 (2002) 97-105
16. Kempuraj D., Devi R.S., Madhappan B., Conti P., Nazer M.Y., Christodoulou S., Reginald J., Suthinthirarajan N., and Namasivayam A. T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors. Int. J. Immunopathol. Pharmacol. 17 (2004) 57-64
17. Lampson L.A. Brain tumor immunotherapy: an immunologist's perspective. J. Neuro-Oncol. 64 (2003) 3-11
18. Lesniak M.S., Tyler B.M., Pardoll D.M., and Brem H. Gene therapy for experimental brain tumors using a xenogenic cell line engineered to secrete hIL-2. J. Neuro-Oncol. 64 (2003) 155-160
19. Metelitsa L.S., Wu H.W., Wang H., Yang Y., Warsi Z., Asgharzadeh S., Groshen S., Wilson S.B., and Seeger R.C. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 199 (2004) 1213-1221
20. Mitchell D.A., Fecci P.E., and Sampson J.H. Adoptive immunotherapy for malignant glioma. Cancer J. 9 (2003) 157-166
21. Molina-Holgado F., Grencis R., and Rothwell N.J. Actions of exogenous and endogenous IL-10 on glial responses to bacterial LPS/cytokines. Glia 33 (2001) 97-106
22. Pawate S., Shen Q., Fan F., and Bhat N.R. Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J. Neurosci. Res. 77 (2004) 540-551
23. Plautz G.E., Barnett G.H., Miller D.W., Cohen B.H., Prayson R.A., Krauss J.C., Luciano M., Kangisser D.B., and Shu S. Systemic T cell adoptive immunotherapy of malignant gliomas. J. Neurosurg. 89 (1998) 42-51
24. Plautz G.E., Mukai S., Cohen P.A., and Shu S. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J. Immunol. 165 (2000) 3656-3662
25. Prins R.M., and Liau L.M. Cellular immunity and immunotherapy of brain tumors. Front. Biosci. 9 (2004) 3124-3136
26. Prins R.M., Graf M.R., and Merchant R.E. Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis. Cancer Immunol. Immunother. 50 (2001) 285-292
27. Proescholdt M.A., Merrill M.J., Ikejiri B., Walbridge S., Akbasak A., Jacobson S., and Oldfield E.H. Site-specific immune response to implanted gliomas. J. Neurosurg. 95 (2001) 1012-1019
28. Sampath P., Hanes J., DiMeco F., Tyler B.M., Brat D., Pardoll D.M., and Brem H. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res. 59 (1999) 2107-2114
29. Shoemaker A.R., Moser A.R., Midgley C.A., Clipson L., Newton M.A., and Dove W.F. A resistant genetic background leading to incomplete penetrance of intestinal neoplasia and reduced loss of heterozygosity in ApcMin/+ mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 10826-10831
30. Spiotto M.T., Yu P., Rowley D.A., Nishimura M.I., Meredith S.C., Gajewski T.F., Fu Y.X., and Schreiber H. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17 (2002) 737-747
31. Sun D., Newman T.A., Perry V.H., and Weller R.O. Cytokine-induced enhancement of autoimmune inflammation in the brain and spinal cord: implications for multiple sclerosis. Neuropathol. Appl. Neurobiol. 30 (2004) 374-384
32. Tsuji T., Chamoto K., Funamoto H., Kosaka A., Matsuzaki J., Abe H., Fujio K., Yamamoto K., Kitamura T., Togashi Y., Koda T., and Nishimura T. An efficient method to prepare T cell receptor gene-transduced cytotoxic T lymphocytes type 1 applicable to tumor gene cell-therapy. Cancer Sci. 94 (2003) 389-393
33. Udaka K., Wiesmuller K.H., Kienle S., Jung G., and Walden P. Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J. Immunol. 157 (1996) 670-678
34. Weiner H.L. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch. Neurol. 61 (2004) 1613-1615
35. Wright D., Schneider A., and Berger J.R. Central nervous system opportunistic infections. NeuroImaging Clin. N. Am. 7 (1997) 513-525
36. Wu M.X., Tsomides T.J., and Eisen H.N. Tissue distribution of natural peptides derived from a ubiquitous dehydrogenase, including a novel liver-specific peptide that demonstrates the pronounced specificity of low affinity T cell reactions. J. Immunol. 154 (1995) 4495-4502
37. Zha Y., Blank C., and Gajewski T.F. Negative regulation of T-cell function by PD-1. Crit. Rev. Immunol. 24 (2004) 229-237
38. Zippelius A., Batard P., Rubio-Godoy V., Bioley G., Lienard D., Lejeune F., Rimoldi D., Guillaume P., Meidenbauer N., Mackensen A., Rufer N., Lubenow N., Speiser D., Cerottini J.C., Romero P., and Pittet M.J. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64 (2004) 2865-2873